Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium
Six oral presentations highlight Signatera’s expanding role across solid tumors, including definitive predictive data in adjuvant bladder cancer
Bladder Cancer Highlights
The IMvigor011 trial, sponsored by
MRD analysis from the Phase 3 CheckMate 274 trial will also be shared in an oral presentation on
Additional ESMO Data
Additional oral presentations include results from the SunRISe-4 trial in MIBC, the INTERCEPT trial in colorectal cancer, and Natera’s early cancer detection program.
“Across multiple different Phase 3 trials, we’ve now shown how Signatera MRD can help identify patients with bladder cancer who are most likely to benefit from adjuvant immunotherapy,” said
“We are proud to showcase the breadth of research using Signatera at this year’s
Full list of presentations featuring Natera’s technology at ESMO includes:
Presenter:
Adjuvant nivolumab vs placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274
Presenter:
Neoadjuvant gemcitabine intravesical system (TAR-200) + cetrelimab (CET) or CET alone in patients (pts) with muscle-invasive bladder cancer (MIBC): SunRISe-4 (SR-4) primary analysis and biomarker results
Presenter:
Treatment response using a tumor-informed circulating DNA test (TIctDNA) comparing with radiologic outcomes in non-small cell lung cancer (NSCLC)
Presenter:
Utility of circulating tumor DNA (ctDNA) dynamics for evaluating early treatment response in patients with recurrent/metastatic endometrial (rEC) and recurrent/platinum-resistant ovarian cancer (rPROC)
Presenter:
Clinical Performance of a Tumor-Informed Whole Genome-Based (WGS) ctDNA Assay for Recurrence Detection and Treatment Response Monitoring in Localized and Advanced/Metastatic Renal Cell Carcinoma (RCC)
Presenter:
Association of ultrasensitive whole genome sequencing (WGS)-based tumor-informed molecular residual disease (MRD) detection with lymph node metastasis (LNM) after local excision of pathological T1 colorectal cancer: Results from DENEB, a CIRCULATE-Japan GALAXY substudy
Presenter:
Performance of a blood-based, early cancer detection (ECD) screening test for colorectal cancer (CRC) in cell-free (cf)DNA
Presenter:
Circulating tumor DNA (ctDNA) clearance and correlation with outcome in the INTERCEPT colorectal cancer (CRC) study
Presenter:
A Phase II Study of mFOLFOXIRI Following Metastasectomy in Oligometastatic Colorectal Cancer: (FANTASTIC)
Presenter:
Neoadjuvant immunotherapy induces immune activation and responses in MMR-proficient colon cancers
Presenter:
HEROES: De-escalation of anti-HER2 therapies in HER2-positive metastatic breast cancer with long-term persistent response and undetectable minimal residual disease in circulating tumor DNA
Presenter:
Hormonal and immune mediators of resistance to primary endocrine therapy
Presenter:
Circulating tumor DNA detection in stage 1 HER2 positive and triple negative breast cancer (SAFE-DE)
Presenter:
IMvigor011: a Phase 3 trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer
Notes
Tecentriq® (atezolizumab) is a registered trademark of
About Natera
Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 300 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in
Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20251012582962/en/
Investor Relations:
Media:
Source:
